"Barclays analyst Emily Field raised Eli Lilly's price target to $1,400, emphasizing the strong momentum of tirzepatide, which is central to the company's growth strategy. The recent earnings report showcased a 56% year-over-year revenue increase, driven by significant contributions from Mounjaro and Zepbound, indicating robust demand and market expansion."
"Eli Lilly's Q1 2026 revenue reached $19.8 billion, exceeding consensus estimates by 11%. Mounjaro's sales surged by 125% year-over-year, while Zepbound's U.S. sales increased by 80%. This performance reflects the effectiveness of the company's GLP-1 products and their potential for future growth."
Barclays analyst Emily Field increased Eli Lilly's price target to $1,400, citing strong momentum from tirzepatide. The company's Q1 2026 revenue rose 56% YoY to $19.8 billion, surpassing estimates. Mounjaro and Zepbound significantly contributed to revenue growth, with Mounjaro achieving $8.66 billion in sales. Eli Lilly's CEO raised full-year revenue guidance to $82 billion to $85 billion. The FDA approved Foundayo, a new GLP-1 pill, and Retatrutide showed promising Phase 3 results, enhancing the company's growth outlook despite pricing fluctuations.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]